2-(1,3-二氧代异吲哚啉-2-基)-N-苯乙酰胺和2-(3,4-二氢异喹啉-1-基)异吲哚-1,3-二酮类单胺氧化酶(MAO)和胆碱酯酶(ChE)抑制剂的设计、合成和生物活性研究

doi:10.6023/cjoc202311027

有机化学 ›› 2024, Vol. 44 ›› Issue (6): 1907-1919.DOI: 10.6023/cjoc202311027 上一篇下一篇

研究论文

2-(1,3-二氧代异吲哚啉-2-基)-N-苯乙酰胺和2-(3,4-二氢异喹啉-1-基)异吲哚-1,3-二酮类单胺氧化酶(MAO)和胆碱酯酶(ChE)抑制剂的设计、合成和生物活性研究

胡懿鸣^a,†, 许嘉宇^a,†, 汤敏^a, 刘雅雯^a, 关丽萍^a^,^*(), 金晴昊^b^,^*()

a 浙江海洋大学食品与药学学院浙江舟山 316022
b 浙江药科职业大学护理学院浙江宁波 315153

收稿日期:2023-11-24 修回日期:2024-01-22 发布日期:2024-03-12
作者简介:
^†共同第一作者
基金资助:
福建省药物新靶点研究重点实验室开放课题资助(FJ-YW-2023KF04); 国家级大学生创新创业训练计划(202310340048)

Design, Synthesis and Biological Activity Studies of 2-(1,3-Dioxoiso-indolin-2-yl)-N-phenethylacetamide and 2-(3,4-Dihydroisoquinolin-1-yl)isoindole-1,3-dione as Monoamine Oxidase (MAO) and Cholinesterase (ChE) Inhibitors

Yiming Hu^a,†, Jiayu Xu^a,†, Min Tang^a, Yawen Liu^a, Liping Guan^a,*(), Qinghao Jin^b,*()

a Food and Pharmacy College, Zhejiang Ocean University, Zhoushan, Zhejiang 316022
b College of Nursing, Zhejiang Pharmaceutical University, Ningbo, Zhejiang 315153

Received:2023-11-24 Revised:2024-01-22 Published:2024-03-12
Contact: * E-mail: glp730@zjou.edu.cn; qhjin2012@163.com
About author:
^†These authors contributed equally to this work.
Supported by:
Fujian Provincial Key Laboratory of Innovative Drug Target Research(FJ-YW-2023KF04); National College Student Innovation and Entrepreneurship Training Program(202310340048)

文章分享

1. 241907S.pdf.pdf(22312KB)

摘要/Abstract

合成了一系列2-(1,3-二氧代异吲哚啉-2-基)-N-苯乙酰胺和2-(3,4-二氢异喹啉-1-基)异吲哚-1,3-二酮衍生物, 并评价了它们抑制单胺氧化酶(MAO)和胆碱酯酶(ChE)生物活性. 实验结果显示, 所有的化合物对单胺氧化酶具有一定的抑制活性. 再分别进行单胺氧化酶A (MAO-A)和单胺氧化酶B (MAO-B)抑制活性研究, 发现所有化合物对MAO-B显示比较好的抑制活性, 对MAO-A显示弱的抑制活性. 其中, 2-(1,3-二氧代异吲哚-2-基)-N-(4-氟苯基乙基)乙酰胺(2h)和2-((7-甲氧基-3,4-二氢异喹啉-1-基)甲基)异吲哚-1,3-二酮(3d)显示最好的抑制MAO-A和MAO-B作用, 对MAO的IC₅₀值分别为(3.87±0.59)和(3.35±0.53) μmol/L. 细胞毒性实验结果显示, 抑制活性比较好的化合物对L929细胞没有细胞毒性. 化合物2h和3d分子对接的结果表明, 化合物2h和3d与MAO-A和MAO-B之间存在明显的相互作用. 另外, 所有的化合物对乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BuChE)显示比较弱的抑制活性.

关键词: 2-(1,3-二氧代异吲哚啉-2-基)-N-苯乙酰胺, 2-(3,4-二氢异喹啉-1-基)异吲哚-1,3-二酮, 单胺氧化酶, 胆碱酯酶, 细胞毒性, 分子对接

A series of 2-(1,3-dioxoisoindolin-2-yl)-N-phenethylacetamide and 2-(3,4-dihydroisoquinolin-1-yl)isoindole- 1,3-dione derivatives were synthesized and their biological activities of monoamine oxidase (MAO) and cholinesterase (ChE) inhibition were evaluated. The experimental results showed that all compounds exhibited certain inhibitory activity against MAOs. Upon separate monoamine oxidase A (MAO-A) and monoamine oxidase A (MAO-B) activity were studied, the compounds displayed better inhibition activity against MAO-B and weaker inhibition activity against MAO-A. Among these, 2-(1,3-dioxoisoindolin-2-yl)-N-(4-fluorophenethyl)acetamide (2h) and 2-((7-methoxy-3,4-dihydroisoquinolin-1-yl)methyl)iso- indoline-1,3-dione (3d) exhibited the most significant inhibition of MAO-A and MAO-B, with IC₅₀ values of (3.87±0.59) and (3.35±0.53) μmol/L towards MAO, respectively. Results from cytotoxicity assays indicated that compounds with good inhi-bitory activity showed no cytotoxicity against L929 cells. Molecular docking of compounds 2h and 3d revealed significant interactions between the active analogs and amino acid residues of the protein receptors. Additionally, all compounds exhibited relatively weak inhibition activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).

Key words: 2-(1,3-dioxoisoindolin-2-yl)-N-phenethylacetamide, 2-(3,4-dihydroisoquinolin-1-yl)isoindole-1,3-dione, monoamine oxidase, cholinesterase, cytotoxicity, molecular docking

引用此文

胡懿鸣, 许嘉宇, 汤敏, 刘雅雯, 关丽萍, 金晴昊. 2-(1,3-二氧代异吲哚啉-2-基)-N-苯乙酰胺和2-(3,4-二氢异喹啉-1-基)异吲哚-1,3-二酮类单胺氧化酶(MAO)和胆碱酯酶(ChE)抑制剂的设计、合成和生物活性研究[J]. 有机化学, 2024, 44(6): 1907-1919.

Yiming Hu, Jiayu Xu, Min Tang, Yawen Liu, Liping Guan, Qinghao Jin. Design, Synthesis and Biological Activity Studies of 2-(1,3-Dioxoiso-indolin-2-yl)-N-phenethylacetamide and 2-(3,4-Dihydroisoquinolin-1-yl)isoindole-1,3-dione as Monoamine Oxidase (MAO) and Cholinesterase (ChE) Inhibitors[J]. Chinese Journal of Organic Chemistry, 2024, 44(6): 1907-1919.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

图/表 11

参考文献 46

[1]	Stefanie, A.; Iyengar, R. E.; Rebecca, S.; Bencie, N. M.; Jeenu, A. M.; Rahul, E.; Adrien, A. J. Drug targeting. 2020, 28, 10.
[2]	Lehn, A.; Gelauff, J.; Hoeritzauer, I.; Ludwig, L.; McWhirter, L.; Williams, S.; Gardiner, P.; Carson, A.; Stone, J. J. Neurol. 2016, 263, 611.
[3]	Mishra, A.; Bandopadhyay, R.; Singh, P. K.; Mishra, P. S.; Sharma, N.; Khurana, N. Metab. Brain Dis. 2021, 36, 1591.
[4]	Furmark, T. Isr. Ann. Psychiatry Relat. Discip. 2009, 46, 5.
[5]	Lane, C. A.; Hardy, J.; Schott, J. M. Eur. J. Neurol. 2018, 25, 59. doi: 10.1111/ene.13439 pmid: 28872215
[6]	Mantzavinos, V.; Alexiou, A. Curr. Alzheimer Res. 2017, 14, 1149. doi: 10.2174/1567205014666170203125942 pmid: 28164766
[7]	Weller, J.; Budson, A. Eur. J. Neurol. 2019, 5, 43.
[8]	Li, Y. Y.; Tang, Q.; Zheng, L. F.; He, D.; Jian, S.; Zhang, M. Eur. J. Med. Chem. 2020, 166, 49.
[9]	Xing, S.; Sun, H. P. Pharm. Prog. 2023, 47, 179. (in Chinese)
	(邢帅帅, 孙昊鹏, 药学进展, 2023, 47, 179.)
[10]	Marucci, G.; Buccioni, M.; Ben, D. D.; Lambertucci, C.; Volpinim, R.; Amenta, F. J. Neurol. 2021, 190, 108352.
[11]	Anand, P.; Singh, B. Arch. Pharm. Res. 2013, 36, 375.
[12]	Caraci, F.; Copani, A.; Nicoletti, F.; Drago, F. Eur. J. Pharmacol. 2010, 626, 64.
[13]	Tune, L. E. Eur. J. Pharmacol. 2008, 8, 91.
[14]	Liu, Y. H.; Xu, H. D.; Dong, X. H.; Zhang, N.; Luo, X. T.; Zhang, H.; Liu, B. Chin. Herb. Med. 2023, 7, 1836. (in Chinese)
	(刘彦宏, 徐红丹, 董晓红, 张宁, 罗孝廷, 张红, 刘斌, 中药材, 2023, 7, 1836.)
[15]	Liu, F.; Zhou, Y. J. Clin. Psychosom. Dis. 2007, 3, 251. (in Chinese)
	(刘峰, 周艳, 临床心身疾病杂志, 2007, 3, 251.)
[16]	Bhawna-Kumar, A.; Bhatia, M.; Kapoor, A.; Kumar, P.; Kumar, S. Eur. J. Med. Chem. 2022, 242, 114655.
[17]	Özdemir, Z.; Alagöz, M. A.; Bahçecioğlu, Ö. F.; Gök, S. Curr. Med. Chem. 2021, 28, 6045. doi: 10.2174/0929867328666210203204710 pmid: 33538661
[18]	Carradori, S.; Secci, D.; Petzer, J. P. Expert Opin. Ther. Pat. 2018, 3, 211.
[19]	Zhang, N. Med. Theory Pract. 2015, 28, 1713. (in Chinese)
	(张娜, 医学理论与实践, 2015, 28, 1713.)
[20]	Mzezewa, S. C.; Omoruyi, S. I.; Zondagh, L. S.; Malan, S. F.; Ekpo, O. E.; Joubert, J. J. Enzyme Inhib. Med. Chem. 2021, 36, 1607.
[21]	Sang, Z. P.; Song, Q.; Cao, Z. C.; Deng, Y.; Zhang, L. J. Enzyme Inhib. Med. Chem. 2022, 37, 69.
[22]	Das, T.; Saha, S. C.; Sunita, K. S. Afr. J. Bot. 2022, 11, 146.
[23]	Zhang, H. H. M.S. Thesis, Lanzhou University, Lanzhou, 2022. (in Chinese)
	(张红花, 硕士论文, 兰州大学, 兰州, 2022.)
[24]	Unzeta, M.; Esteban, G.; Bolea, I.; Fogel, W. A.; Ramsay, R. R.; Youdim, M. B.; Tipton, K. F.; Marco-Contelles, J. Front. Neurosci. 2016, 10, 205.
[25]	Zhang, M.; Zhang, H.; Zheng, J. X.; Mo, H.; Xia, K. F.; Jian, S. G. Int. J. Mol. Sci. 2018, 19, 3446.
[26]	Plazas, E.; Avila, M. C.; Muñoz, D. R.; Cuca, S. L. E. Pharmacol. Res. 2022, 177, 106126.
[27]	Zou, X. H.; Fu, X. Q.; Wang, W. W. Cardiovasc. Dis. J. Integr. Tradit. Chin. West Med. 2023, 21, 3497. (in Chinese)
	(邹旭欢, 付雪琴, 王玮玮, 中西医结合心脑血管病杂志, 2023, 21, 3497.)
[28]	Bonnet, U. CNS Drug Rev. 2003, 9, 140.
[29]	Behlke, L. M.; Lenze, E. J.; Carney, R. M. CNS Drugs 2020, 34, 1133.
[30]	Liang, Y.; Zhang, L.; Zeng, Z. C. Chin. J. New Drugs 2018, 27, 1603. (in Chinese)
	(梁瑶, 张蕾, 曾灶昌, 中国新药杂志, 2018, 27, 1603.)
[31]	Pan, S. L.; Xie, J.; Qian, F. G.; Wang, J.; Shao, Y. C. Acta Pharm. Sin. 2005, 4, 355. (in Chinese)
	(潘胜利, 解静, 钱伏刚, 王峻, 邵衣慈, 药学学报, 2005, 4, 355.)
[32]	Verma, S.; Lal, S.; Narang, R.; Sudhakar, K. Chem. Med. Chem. 2023, 18, e202200571.
[33]	Teng, P.; Li, C.; Peng, Z.; Anne, M. V.; Nimmagadda, A.; Su, M.; Li, Y.; Sun, X.; Cai, J. Bioorg. Med. Chem. 2018, 26, 3573.
[34]	Guan, L. P.; Jin, Q. H.; Tian, G. R.; Chai, K. Y.; Quan, Z. S. J. Pharm. Pharm. Sci. 2007, 10, 254.
[35]	Pässler, U.; Knölker, H. J. Alkaloids Chem. Biol. 2011, 70, 79. pmid: 22308756
[36]	Bhadra, K.; Kumar, G. S. Mini. Rev. Med. Chem. 2010, 10, 1235.
[37]	Jason, D. J. M.; Norman, H.; Rigdon, G. A. J. Med. Chem. 2016, 39, 149.
[38]	Kong, X. P.; Chen, Z. Z.; Xia, Y. J.; Ren, H. Q.; Dong, T. X.; Zhan, H. Q. J. Liaoning Univ. Tradit. Chin. Med. 2021, 23, 35. (in Chinese)
	(孔祥鹏, 陈志从, 夏英杰, 任海琴, 董婷霞, 詹华强, 辽宁中医药大学学报, 2021, 23, 35.)
[39]	Guo, H. M.; Lu, Z. H.; Chen, S. Q.; Yu, Y. Asian J. Chem. 2015, 10, 3651.
[40]	Xi, M. Y.; Jia, J. M.; Sun, H. P.; Sun, Z. Y.; Jiang, J. W.; Wang, Y. J.; Zhang, M. Y. J. Med. Chem. 2013, 56, 7925.
[41]	Gan, L. L.; Gan, Z. J.; Gan, Z. J.; Dan, Y. R.; Zhang, P. M. J. Med. Chem. 2021, 64, 1018.
[42]	Grenier, D.; Audebert, S.; Preto, J.; Guichou, J. F.; Krimm, I. Expert Opin. Drug Discovery 2023, 18, 987.
[43]	Xia, M. L.; Niu, W. W.; Lin, D. Z. J. Tianjin Med. Univ. 2023, 29, 349. (in Chinese)
	(夏梦琳, 牛菀菀, 林道正, 天津医科大学学报, 2023, 29, 349.)
[44]	Hansen, M.; Bonner, L. A.; Cueva, J. P.; Maglathlin, R.; Nichols, D. E. ACS Chem. Neurosci. 2013, 4, 96.
[45]	Ellman, G. L.; Courteny, K. D.; Andres, V.; Feather, R. M.. Biochem. Pharmacol. 1961, 7, 88.
[46]	Paulson, J. R.; Vander, E. R.; Dillinger, E.; Luedeman, M. E.; Usman, B. Chromosome Res. 2022, 30, 351. doi: 10.1007/s10577-022-09709-1 pmid: 36399199

Compd.	R	Inhibition rate/%	IC₅₀/(μmol•L^–1)
2a	H	67.59	6.00±0.77
2b	4-CH₃	62.21	4.42±0.61
2c	2-OCH₃	41.83	14.03±1.14
2d	4-OCH₃	64.21	4.09±0.61
2e	3,4-(OCH₃)₂	58.82	5.23±0.72
2f	2-F	41.83	14.73±1.16
2g	3-F	68.63	3.64±0.56
2h	4-F	66.01	3.87±0.59
2i	4-Cl	86.27	6.34±0.95
2j	2-Br	60.13	6.18±0.79
2k	3-Br	65.36	4.94±0.60
2l	4-Br	35.95	15.93±1.45
3a	H	80.66	5.29±2.24
3b	4-CH₃	61.56	4.55±0.60
3c	2-OCH₃	38.57	13.5±1.55
3d	4-OCH₃	91.98	3.35±0.53
3e	3,4-(OCH₃)₂	52.72	9.40±1.76
3f	2-F	63.68	4.17±0.64
3g	3-F	79.25	3.91±0.60
3h	4-F	96.70	1.53±0.19
3i	4-Cl	79.48	3.94±1.43
3j	2-Br	87.27	3.10±0.36
3k	3-Br	76.42	4.86±0.69
3l	4-Br	50.47	9.58±0.44
Rasagiline	—	88.30	1.68±0.75

Compd.	R	Inhibition rate/%	IC₅₀/(μmol•L^–1)
2a	H	67.59	6.00±0.77
2b	4-CH₃	62.21	4.42±0.61
2c	2-OCH₃	41.83	14.03±1.14
2d	4-OCH₃	64.21	4.09±0.61
2e	3,4-(OCH₃)₂	58.82	5.23±0.72
2f	2-F	41.83	14.73±1.16
2g	3-F	68.63	3.64±0.56
2h	4-F	66.01	3.87±0.59
2i	4-Cl	86.27	6.34±0.95
2j	2-Br	60.13	6.18±0.79
2k	3-Br	65.36	4.94±0.60
2l	4-Br	35.95	15.93±1.45
3a	H	80.66	5.29±2.24
3b	4-CH₃	61.56	4.55±0.60
3c	2-OCH₃	38.57	13.5±1.55
3d	4-OCH₃	91.98	3.35±0.53
3e	3,4-(OCH₃)₂	52.72	9.40±1.76
3f	2-F	63.68	4.17±0.64
3g	3-F	79.25	3.91±0.60
3h	4-F	96.70	1.53±0.19
3i	4-Cl	79.48	3.94±1.43
3j	2-Br	87.27	3.10±0.36
3k	3-Br	76.42	4.86±0.69
3l	4-Br	50.47	9.58±0.44
Rasagiline	—	88.30	1.68±0.75

Compd.	R	Inhibition rate/%		IC₅₀/(μmol•L^–1) of MAO-B
Compd.	R	MAO-A	MAO-B	IC₅₀/(μmol•L^–1) of MAO-B
2a	H	58.06	76.80	5.20±1.83
2b	4-CH₃	22.58	65.46	7.27±0.86
2c	2-OCH₃	42.42	38.85
2d	4-OCH₃	32.26	61.60	7.47±1.62
2e	3,4-(OCH₃)₂	22.64	78.98	5.58±0.75
2f	2-F	21.21	44.94
2g	3-F	20.97	30.15
2h	4-F	64.52	75.26	5.02±0.70
2i	4-Cl	29.03	63.14	7.36±1.75
2j	2-Br	66.04	10.83
2k	3-Br	3.23	30.41
2l	4-Br	60.61	31.44
3a	H	31.25	1.37
3b	4-CH₃	34.38	21.92
3c	2-OCH₃	69.7	69.59	7.41±2.76
3d	4-OCH₃	78.75	89.04	4.82±0.83
3e	3,4-(OCH₃)₂	27.42	74.23	4.94±0.69
3f	2-F	28.13	8.90
3g	3-F	25.00	71.23	4.84±1.25
3h	4-F	15.63	35.65
3i	4-Cl	4.69	72.60	4.86±1.35
3j	2-Br	21.88	49.32
3k	3-Br	34.38	78.08	5.40±0.73
3l	4-Br	26.56	35.62

Compd.	R	Inhibition rate/%		IC₅₀/(μmol•L^–1) of MAO-B
Compd.	R	MAO-A	MAO-B	IC₅₀/(μmol•L^–1) of MAO-B
2a	H	58.06	76.80	5.20±1.83
2b	4-CH₃	22.58	65.46	7.27±0.86
2c	2-OCH₃	42.42	38.85
2d	4-OCH₃	32.26	61.60	7.47±1.62
2e	3,4-(OCH₃)₂	22.64	78.98	5.58±0.75
2f	2-F	21.21	44.94
2g	3-F	20.97	30.15
2h	4-F	64.52	75.26	5.02±0.70
2i	4-Cl	29.03	63.14	7.36±1.75
2j	2-Br	66.04	10.83
2k	3-Br	3.23	30.41
2l	4-Br	60.61	31.44
3a	H	31.25	1.37
3b	4-CH₃	34.38	21.92
3c	2-OCH₃	69.7	69.59	7.41±2.76
3d	4-OCH₃	78.75	89.04	4.82±0.83
3e	3,4-(OCH₃)₂	27.42	74.23	4.94±0.69
3f	2-F	28.13	8.90
3g	3-F	25.00	71.23	4.84±1.25
3h	4-F	15.63	35.65
3i	4-Cl	4.69	72.60	4.86±1.35
3j	2-Br	21.88	49.32
3k	3-Br	34.38	78.08	5.40±0.73
3l	4-Br	26.56	35.62

2-(1,3-二氧代异吲哚啉-2-基)-N-苯乙酰胺和2-(3,4-二氢异喹啉-1-基)异吲哚-1,3-二酮类单胺氧化酶(MAO)和胆碱酯酶(ChE)抑制剂的设计、合成和生物活性研究

Design, Synthesis and Biological Activity Studies of 2-(1,3-Dioxoiso-indolin-2-yl)-N-phenethylacetamide and 2-(3,4-Dihydroisoquinolin-1-yl)isoindole-1,3-dione as Monoamine Oxidase (MAO) and Cholinesterase (ChE) Inhibitors

RichHTML

PDF

补充材料

可视化

摘要/Abstract

引用此文

分享此文

图/表 11

参考文献 46

相关文章 15

编辑推荐

相关统计

本文评价

[1]	秦丽清, 林桂汕, 段文贵, 崔玉成, 杨卯芳, 李芳耀, 李典鹏. 新型长叶烯基萘满并N-酰基吡唑化合物的合成、抗增殖活性、三维定量构效关系及分子对接研究[J]. 有机化学, 2024, 44(6): 1967-1977.
[2]	梁国超, 董婷婷, 纪海莹, 王春艳, 宋亚丽, 张伟. 新型3,3'-((4-氯-2H-硫色烯-3-基)亚甲基)双(1H-吲哚)类拓扑异构酶Ⅱ抑制剂的合成及抗肿瘤活性研究[J]. 有机化学, 2024, 44(6): 1949-1956.
[3]	朱红波, 王吉, 胡炜彦, 周堂, 林芷淇, 张荣平, 耿长安, 陈兴龙. 大狼毒根茎中对胰腺癌SW1990细胞具有毒性的二萜[J]. 有机化学, 2024, 44(6): 1929-1937.
[4]	裴鸿艳, 叶家麟, 王锋, 刘东东, 余裕奎, 张静, 张立新. 新型含哌啶结构的脲嘧啶类化合物的设计合成与除草活性研究[J]. 有机化学, 2024, 44(5): 1592-1605.
[5]	吴思敏, 唐嘉欣, 周于佳, 徐学涛, 张昊星, 王少华. 2β-Acetoxyferruginol去醋酸基骨架衍生物抑制α-葡萄糖苷酶活性研究[J]. 有机化学, 2024, 44(2): 613-621.
[6]	王锋, 陈钰, 裴鸿艳, 张静, 张立新. 含哌啶的新型1,2,4-噁二唑类衍生物的设计合成及抗真菌活性研究[J]. 有机化学, 2023, 43(8): 2826-2836.
[7]	刘敏, 杨冬燕, 肖玉梅, 苏旺苍, 赵峰海, 覃兆海. 5-硝基亚氨基[1,4-2H]-1,2,4-三唑啉烯式吡虫啉类似物的合成及生物活性研究[J]. 有机化学, 2023, 43(8): 2790-2799.
[8]	徐欢, 吴鸿飞, 张晓鸣, 路星星, 孙腾达, 亓悦, 林誉凡, 杨新玲, 张莉, 凌云. 含1,2,3,4-四氢异喹啉片段磺酰肼和酰肼类化合物的设计、合成及生物活性研究[J]. 有机化学, 2023, 43(2): 725-733.
[9]	孙昌兴, 张福豪, 张欢, 李鹏辉, 姜林. 新型2-(1-甲基-1H-吡唑-4-基)嘧啶-4-甲酰胺的设计、合成、杀菌活性及分子对接研究[J]. 有机化学, 2023, 43(1): 229-235.
[10]	李蕾, 朱聪聪, 朱全刚, 陈中建, 高希珂. 愈创木薁衍生物的设计合成及其抗氧化、抗炎活性研究[J]. 有机化学, 2022, 42(9): 2906-2913.
[11]	王长凯, 孙腾达, 张学博, 杨新玲, 路星星, 徐欢, 石发胜, 张莉, 凌云. 新型含氟吡唑酰肼类化合物的设计合成与生物活性研究[J]. 有机化学, 2022, 42(5): 1527-1536.
[12]	赵永梅, 穆叶舒, 罗稳, 田智勇. 胆碱酯酶抑制剂萘酰亚胺衍生物的合成与聚集诱导发光性质[J]. 有机化学, 2022, 42(3): 819-829.
[13]	王秀, 段文贵, 林桂汕, 李宝谕, 张文静, 雷福厚. 含天然蒎烯结构的4-酰基-3-氨基-1,2,4-三唑-硫醚衍生物的合成、抑菌活性、三维定量构效关系及分子对接研究[J]. 有机化学, 2022, 42(3): 871-883.
[14]	孔媛芳, 杨彬, 庄严, 张京玉, 孙德梅, 董春红. 基于二肽基肽酶4 (DPP-4)靶点设计的五种降糖活性杂环合成及构效关系研究进展[J]. 有机化学, 2022, 42(3): 770-784.
[15]	崔玉成, 陈美桦, 林桂汕, 段文贵, 李晴敏, 邹壬萱, 岑波. 含偕二甲基环丙烷结构的1,3,4-噻二唑-脲化合物的合成、抑菌活性及分子对接研究[J]. 有机化学, 2022, 42(11): 3784-3797.